Building The Biotech City: Is Los Angeles The Go-To Destination For Tomorrow’s Drug Innovations?
Round Table Discussion: Positioning Los Angeles As The Next Big Biotech Hub
The complexity of producing viable drug candidates is increasing as an abundance of new science keeps extending the range of possible targets and fragmenting disease subtypes. Proximity to novel exploratory research is a driver of pipeline productivity – so can physical location within a communal geography of well-resourced intellectual firepower raise the odds for R&D success? In Vivo sits down with eight key leaders in academia, VC, commercial real estate and groundbreaking biotech to discuss how Los Angeles – the “out there” city of out-sized ambitions – is positioning itself for global leadership in the curative technologies of the future.
You may also be interested in...
As the global access debate adapts to the stark inequities exposed by the COVID-19 pandemic, the UN-backed Medicines Patent Pool is emerging as a key player on issues ranging from vaccine tech transfer to making more drugs affordable against the spread of non-communicable diseases like cancer to middle- and low-income countries.
Powered by prominent global health philanthropies and the UK’s world-class collaborative capabilities in disease surveillance, the new International COVID-19 Data Alliance (ICODA) is gearing up to address a crucial – and yet unanswered – policy question for public health: can sharing data curated from a diversity of sources provide the hard evidence needed to improve patient outcomes against the virus – not just for today’s pandemic, but for future ones as well? Much will depend on a robust response from big pharma.
Venture capital funds in Latin America have overlooked biotech, leaving an untapped opportunity for local capital markets and US and European investors alike. Chilean entrepreneur Cristian Hernandez, founder of newly launched boutique VC Zentynel Frontier Investments, explains how business – and society – can benefit from launching biotech start-ups able to serve a global market at lower cost.